Esperion Therapeutics ESPR Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Par or Stated Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's preferred stock, par or stated value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's preferred stock, par or stated value per share?
- Esperion Therapeutics (ESPR) reported preferred stock, par or stated value per share of $0 in Q1 2026.
- How has Esperion Therapeutics's preferred stock, par or stated value per share changed year-over-year?
- Esperion Therapeutics's preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Esperion Therapeutics's preferred stock, par or stated value per share?
- Over 5 years (2020 to 2025), Esperion Therapeutics's preferred stock, par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.